Should You Buy Henry Schein, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Henry Schein, Inc. (HSIC) carries a solid Quality of Company rating of 7.4/10. Trading at $87.82, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 3 of 12 CirclFi valuation models project upside for Henry Schein, Inc. (HSIC) at $87.82 — the model consensus leans bearish, with a Quality Score of 7.4/10 and Value-Trap risk of 26/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Target: $156.50 (+78.2% upside)
- According to the CirclFi Quality of Company (QOC) framework, Henry Schein, Inc.'s score of 7.4/10 reflects durable competitive advantages that should sustain earnings power through market cycles.
- According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model targets a fair value of $156.50 (+78.2%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
The Bear Case
Target: $12.68 (-85.6%)
- According to the CirclFi Deep Alpha Valuation Engine, the EROIC Spread model sees the stock as overvalued with a fair value of $12.68 (-85.6%), suggesting that the market price embeds overly optimistic growth assumptions.
- According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +163.8% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.
The Bottom Line
Our valuation engine sends a clear cautionary signal on Henry Schein, Inc. at $87.82. 9/12 models flag overvaluation, composite fair value sits at $59.59 (-32.1%), and the risk-reward profile appears unfavorable. Quality at 7.4/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Henry Schein, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy HSIC stock right now?
Based on CirclFi's multi-model analysis, 3 of 12 models see upside for HSIC at $87.82. The models are divided, which means the investment case depends heavily on your assumptions about Henry Schein, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Henry Schein, Inc.?
Key risks include: wide model disagreement (1135% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Distribution companies. Always diversify and consult a financial advisor.
How does HSIC compare to its competitors?
Among Medical Distribution peers, HSIC holds a Quality Score of 7.4/10. Comparable companies include MCK (QOC 9.6), COR (QOC 9.1), CAH (QOC 8.5). The relative ranking helps investors identify whether HSIC offers better fundamental quality than alternatives in the same sector.
Is HSIC a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. HSIC's Quality Score of 7.4/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy HSIC at?
CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $12.68 to $156.50. At $87.82, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for HSIC.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad